---
title: Discovery on Target 2023
description: Single Cell CEO Chun-Nan Chen’s talk at Discovery on Target 2023, “Screen All, Sequence All, Decide Later,” showcased AbTheneum antibody discovery
image: https://singlecelltechnology.com/hubfs/Untitled%20design%20(7).png
---

<https://singlecelltechnology.com/news>

# Discovery on Target 2023

[ Events ](https://singlecelltechnology.com/news/tag/events) [ Conferences ](https://singlecelltechnology.com/news/tag/conferences) 

 September 25, 2023

Share <https://linkedin.com/sharing/share-offsite/?url=https://singlecelltechnology.com/news/dot-2023> <https://twitter.com/share?url=Discovery+on+Target+2023%20https://singlecelltechnology.com/news/dot-2023> [mailto:?subject=Discovery%20on%20Target%202023&body=https://singlecelltechnology.com/news/dot-2023](mailto:?subject=Discovery%20on%20Target%202023&body=https://singlecelltechnology.com/news/dot-2023)

### September 25-28, 2023

Chun-Nan Chen, Single Cell’s founder and CEO, delivered a talk showcasing our AbTheneum™ antibody discovery platform at Discovery on Target in September.

Titled “Screen All, Sequence All, Decide Later,” his presentation highlighted some of the key benefits researchers have seen with the platform. First: the fact that it delivers antibody sequences, with their associated detailed binding profile, just 2-3 weeks after processing the best cells from harvest. And then, since all of the antibodies are screened and sequenced at once, our ability to extract and provide *all* available data — so users can decide which candidates to advance, a day or a month or a year or more later.   

![DoT 2023 SCT Influenza Poster ](https://singlecelltechnology.com/hs-fs/hubfs/DoT%202023%20SCT%20Influenza%20Poster%2020230817.pptx%20(2)-1.png?width=240&height=320&name=DoT%202023%20SCT%20Influenza%20Poster%2020230817.pptx%20(2)-1.png)Find out more about our AbTheneum platform [here](https://singlecelltechnology.com/our-science).

Chun-Nan also presented a poster — “O Broad Anti-Influenza Antibody, Where Art Thou?”— with a case study on screening for antibodies that bind to several subtypes of influenza hemagglutinin (HA) proteins. Broadly-reactive anti-influenza antibodies could be useful neutralizing influenza or to serve as a diagnostic reagent that is effective across multiple strains of the virus. This case study was created in collaboration with [Miltenyi Biotec](https://www.miltenyibiotec.com/US-en/).

Want to see for yourself? Fill out the form below.

### Download the Poster.

## Related Articles

[![Abtherx Logo](https://singlecelltechnology.com/hs-fs/hubfs/Untitled%20design%20(10)-1.png?width=352&name=Untitled%20design%20(10)-1.png) ](https://singlecelltechnology.com/news/abtherx-partners-with-single-cell-technology)

### [AbTherx Partners with Single Cell Technology for First Antibody Discovery Campaigns](https://singlecelltechnology.com/news/abtherx-partners-with-single-cell-technology)

March 13, 2024  |  Partnership provides AbTherx and licensees of AbTherx’s Atlas™ Mice access to Single Cell Technology's proprietary single B cell screening engine

[![](https://singlecelltechnology.com/hs-fs/hubfs/Screenshot%202024-04-25%20at%2011.17.58%20AM.png?width=352&name=Screenshot%202024-04-25%20at%2011.17.58%20AM.png) ](https://singlecelltechnology.com/news/pegs-2025-trends)

### [What we learned at PEGS 2025](https://singlecelltechnology.com/news/pegs-2025-trends)

May 20, 2025  |  Highlights from the Frontlines of Antibody Discovery and Engineering Read Time: 5 minutes PEGS 2025 brought together platform innovators, AI...

[![](https://singlecelltechnology.com/hs-fs/hubfs/AbTherx%20Vaccinex%20SCT%20logo%20combined.png?width=352&name=AbTherx%20Vaccinex%20SCT%20logo%20combined.png) ](https://singlecelltechnology.com/news/abtherx-sct-vaccinex-collaboration)

### [AbTherx, Single Cell Technology, and Vaccinex Announce Collaboration to Tackle Challenging Antibody Drug Targets](https://singlecelltechnology.com/news/abtherx-sct-vaccinex-collaboration)

May 13, 2025  |  AbTherx and Single Cell Technology incorporate ActivMAb® Technology into Atlas™ Mouse and AbTheneum™ antibody discovery platforms

```json
{
  "@context" : "https://schema.org",
  "@type" : "BlogPosting",
  "author" : {
    "@type" : "Person",
    "name" : "Single Cell Technology",
    "url" : "https://singlecelltechnology.com/news/author/single-cell-technology"
  },
  "dateModified" : "2024-05-15T18:18:11.584Z",
  "datePublished" : "2023-09-25T19:37:00.000Z",
  "headline" : "Discovery on Target 2023",
  "image" : [ "https://singlecelltechnology.com/hubfs/Untitled%20design%20(7).png" ],
  "mainEntityOfPage" : {
    "@id" : "https://singlecelltechnology.com/news/dot-2023",
    "@type" : "WebPage"
  },
  "publisher" : {
    "@type" : "Organization",
    "logo" : {
      "@type" : "ImageObject",
      "url" : "https://singlecelltechnology.com/hubfs/Single%20Cell_Main_Logo_4C-2-1-1.png"
    },
    "name" : "Single Cell Technology"
  }
}
```